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Research Article
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There is compelling evidence for the role of the leucine-rich repeat kinase 2 (LRRK2) and
in particular its kinase function in Parkinson’s disease. Orally bioavailable, brain penetrant
and potent LRRK2 kinase inhibitors are in the later stages of clinical development. Here,
we describe a facile and robust assay to quantify LRRK2 kinase pathway activity by
measuring LRRK2-mediated phosphorylation of Rab10 in human peripheral blood neutro-
phils. We use the selective MJFF-pRab10 monoclonal antibody recognising the Rab10
Thr73 phospho-epitope that is phosphorylated by LRRK2. We highlight the feasibility and
practicability of using our assay in the clinical setting by studying a few patients with
G2019S LRRK2 associated and sporadic Parkinson’s as well as healthy controls. We
suggest that peripheral blood neutrophils are a valuable resource for LRRK2 research and
should be considered for inclusion in Parkinson’s bio-repository collections as they are
abundant, homogenous and express relatively high levels of LRRK2 as well as Rab10. In
contrast, the widely used peripheral blood mononuclear cells are heterogeneous and only
a minority of cells (monocytes and contaminating neutrophils) express LRRK2. While our
LRRK2 kinase pathway assay could assist in patient stratiﬁcation based on LRRK2 kinase
activity, we envision that it may ﬁnd greater utility in pharmacodynamic and target
engagement studies in future LRRK2 inhibitor trials.
Introduction
Parkinson’s disease is a common and complex neurodegenerative disorder affecting ∼1% of people
over the age of 65 [1]. As with other neurodegenerative diseases, the greatest unmet need is the devel-
opment of biomarkers and disease-modifying therapies. The risk for developing Parkinson’s is multi-
factorial and results from an interplay between advancing age, environmental and genetic factors. The
attributable risk of genetic factors ranges from highly penetrant mutations in ∼20 genes that cause rare,
monogenetic forms of Parkinson’s (all together accounting for less than 5–10% of all Parkinson’s cases)
to common variants with a mild-to-moderate effect size [2–4]. The leucine-rich repeat kinase 2
(LRRK2) gene is one of the main genetic contributors and was ﬁrst discovered to be associated with
Parkinson’s in 2004 [5,6]. It is a large (2527 residues, 286 kDa) multi-domain protein including a
ROC/COR GTPase and kinase catalytic domains [5,6]. LRRK2 not only constitutes a pleomorphic risk
factor for developing Parkinson’s, but also links familial and sporadic forms of the disease [7]. The fre-
quency of LRRK2 mutations in autosomal dominant familial Parkinson’s has been estimated to be
∼4% [8,9]. The G2019S LRRK2 mutation is particularly common and varies widely across populations
— it is found in 5–10% of familial cases in Northern Europe and the U.S.A., but with much higher fre-
quency, for example, in Portuguese patients (10%), Ashkenazi Jews (23%) and North African Berbers
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(40%) [10]. Interestingly, the G2019S LRRK2 mutation is also found in 1–2% of sporadic Parkinson’s cases [10].
Its penetrance is incomplete and age-dependent [9]. In addition, there are common protein-coding and
non-protein-coding variants at the LRRK2 locus that moderately increase the risk for developing Parkinson’s [11].
Mounting evidence indicates that all pathogenic mutations, including G2019S, exert their effects by increas-
ing LRRK2 kinase activity. As such there is considerable interest in targeting LRRK2 for the prevention and
possibly treatment of Parkinson’s [12]. Accordingly, pharmaceutical companies have generated highly selective,
orally bioavailable and brain penetrant LRRK2 inhibitors that are in the later stages of clinical development [13].
Recent work has deﬁned a subset of Rab GTPase proteins as the ﬁrst validated physiological substrates of
LRRK2 [14]. LRRK2 directly phosphorylates a conserved Thr/Ser residue residing at the centre of the effector-
binding switch-II motif of many Rab proteins, including Rab10 (Thr73). All LRRK2 pathogenic mutations
tested, including G2019S, increase the phosphorylation of Rab10 in cells (HEK293 and mouse embryonic ﬁbro-
blasts) as well as mouse tissues (brain, spleen, lung and kidney) [14,15]. Speciﬁc phosphorylation of endogen-
ous Rab10 has until now been assessed by either mass spectrometry analysis [14,16,17] or by employing the
Phos-tag reagent which retards the electrophoretic mobility of LRRK2-phosphorylated Rab proteins [15]. As
described in the accompanying paper, we have recently developed a highly sensitive rabbit monoclonal
phospho-antibody (termed MJFF-pRab10) that detects Rab10 phosphorylated at Thr73 by LRRK2 [18].
Importantly, this antibody is highly speciﬁc and does not detect any of the other 13 Rab proteins known to be
phosphorylated by LRRK2, a conclusion conﬁrmed by using Rab10 knockout A549 cells [18].
LRRK2 is also constitutively phosphorylated at a cluster of serine residues that reside in a non-catalytic
region between the Ankyrin domain and the leucine-rich repeat region (Ser910, Ser935, Ser955 and Ser973),
and play a role in regulating 14-3-3 binding as well as cytosolic localisation [19,20]. These sites have received a
lot of attention as they are controlled by LRRK2 kinase activity, and therefore become dephosphorylated in
response to diverse LRRK2 inhibitors [21,22]. Thus, monitoring the dephosphorylation of these residues, espe-
cially Ser935, has become the principal pharmacodynamic marker to assess the in vivo efﬁcacy of LRRK2 inhi-
bitors in cell line and animal models [23]. However, a major drawback of Ser935 phosphorylation is that it
does not correlate with intrinsic cellular LRRK2 kinase activity. For example, knock-in pathogenic mutations
such as G2019S that increase LRRK2 kinase activity and Rab10 phosphorylation ∼2-fold have no effect on
phosphorylation of Ser935 and other nearby phosphosites [14,15]. Moreover, Ser935 is still phosphorylated in
kinase-inactive LRRK2, whereas Ser935 phosphorylation is strongly reduced in pathogenic mutations located in
the ROC/COR GTPase domain that activate LRRK2 kinase activity to a greater extent than the G2019S muta-
tion [15,19,24]. It is also not understood how phosphorylation of Ser935 and its close-by sites is controlled,
and what the upstream kinase or kinases are that phosphorylate(s) these residues. Finally, it is also possible to
assess LRRK2 activity by monitoring autophosphorylation of Ser1292, and phosphorylation of this site corre-
lates well with LRRK2 kinase activity [25]. However, the available phospho-speciﬁc antibodies are insufﬁciently
sensitive and/or phosphorylation stoichiometry is too low, to reliably utilise Ser1292 phosphorylation as a
readout for endogenous LRRK2 kinase activity by immunoblot analysis of whole cell extracts.
In the present study, we explore the feasibility of assessing endogenous LRRK2 kinase activity in peripheral
blood cells by monitoring LRRK2-mediated Rab10 phosphorylation, employing the newly developed
MJFF-pRab10 phospho-speciﬁc rabbit monoclonal antibody [18]. We focus on human peripheral blood neutro-
phils as they constitute a homogenous cell population with high expression levels of both LRRK2 and Rab10.
We argue that neutrophils are better suited than peripheral blood mononuclear cells (PBMCs) to study LRRK2
regulated Rab10 phosphorylation in human peripheral blood. Furthermore, we elaborate methods to quantita-
tively assess LRRK2-mediated Rab10 phosphorylation in human neutrophils including the study of a few clin-
ical samples from LRRK2 G2019S associated and sporadic Parkinson’s patients as well as controls. We
anticipate that our LRRK2 kinase assay in neutrophils could have utility in future clinical trials to (1) assess
LRRK2 pathway activity in Parkinson’s patients, (2) identify patients displaying elevated LRRK2 kinase activity
and (3) monitor pharmacokinetics and target engagement of administered LRRK2 inhibitors.
Materials and methods
Reagents
MLi-2 [26,27] and Phos-tag acrylamide [28] were synthesised at the University of Dundee. The PF-06447475
inhibitor was purchased from R&D systems (#5716), diisopropylﬂuorophosphate (DIFP) was from Sigma (Cat#
D0879) and phenylmethane sulfonyl ﬂuoride (PMSF) was from Sigma (Cat# 78830).
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Antibodies
MJFF-pRab10 rabbit monoclonal antibodies are described in the accompanying paper [18] and used at 1 mg/
ml ﬁnal concentration. This antibody will be made commercially available by the Michael J. Fox Foundation in
the foreseeable future. To enable LI-COR multiplexing of the MJFF-pRab10 rabbit monoclonal antibodies with
a total Rab10 antibody, we commissioned Nanotool Antibodies (http://www.nanotools.de/) to generate a mouse
monoclonal antibody raised against human recombinant Rab10 (sequence 100% identical with mouse). The
resultant antibody, termed MJFF-total Rab10, was highly selective and recognised only a single major band in
wild type but not in previously described Rab10 knockout A549 cells [15] (Supplementary Figure S1). The
MJFF-total Rab10 mouse monoclonal antibody was similarly sensitive and clean as the rabbit anti-Rab10 anti-
body from Cell Signaling Technology (#8127) used at a 1 : 1000 dilution. The selectivity of this antibody has
previously been demonstrated by employing Rab10 knockout A549 cells [15] (Supplementary Figure S1). The
MJFF-total Rab10 antibody will be made commercially available by the Michael J. Fox Foundation in the
future. Total LRRK2 rabbit monoclonal antibody was raised against LRRK2 residues 100–500 (UDD3) and
pS935-LRRK2 (UDD2) [24,29]. These antibodies were puriﬁed at the University of Dundee and used at 1 mg/
ml ﬁnal concentration. Mouse anti-LRRK2 C-terminus antibody was from Antibodies Incorporated (#75-253)
and used at 1 : 1000 dilution. Anti-glyceraldehyde-3-phosphate dehydrogenase (GAPDH) antibody was from
Santa Cruz Biotechnology (sc-32233) and used at 1 : 2000 dilution. Horseradish peroxidase-conjugated anti-
mouse (#31450) and -rabbit (#31460) secondary antibodies were from Thermo Fisher Scientiﬁc and used at 1 :
5000 dilution. Goat anti-mouse IRDye 800CW (#926-32210) and IRDye 680LT (#926-68020) and goat anti-
rabbit IRDye 800CW ((#926-32211) secondary antibodies were from LI-COR.
Study participants and blood sample collection
For setting up and validating the LRRK2-mediated Rab10 assay, we recruited volunteers from within the
School of Life Sciences at the University of Dundee who kindly donated blood for the present study.
Speciﬁcally, the data shown in Figures 2 and 6–10 and Supplementary Figures S2 and S3 are derived from
healthy volunteers from Dundee.
For the clinical part of our study, blood was collected from a total of 26 subjects that were associated with the
Neurology Department at the University of Tuebingen in Germany: seven patients with sporadic Parkinson’s
and ﬁve patients with G2019S LRRK2 associated Parkinson’s as well as 1 G2019S LRRK2 non-manifesting
carrier and 13 healthy controls. Most of the control subjects were enrolled from the well-characterized TREND
(Tubingen evaluation of Risk factors for early detection of neurodegeneration) study as well as some others from
within staff from the Neurology Department and two healthy family members (one unrelated healthy spouse
and one daughter, who had tested negative for the G2019S LRRK2 mutation). Demographics, such as gender,
age, disease duration and ethnicity, were collected. Diagnosis of Parkinson’s was deﬁned according to the UK
Brain Bank criteria with the exception that a positive family history for Parkinson’s was not considered an exclu-
sion criterion [30]. The severity of motor symptoms and the presence of motor complications were assessed
using part III and IV of the Movement disorder society — Uniﬁed Parkinson’s disease rating scale
(MDS-UPDRS-III and -IV) [31]. Cognitive function was tested with the Montreal Cognitive Assessment
(MoCA) [32]. A cut off of <26 out of 30 points indicated cognitive impairment. Levodopa-equivalent daily dose
(LEDD) was recorded as well as any additional non-oral therapies such as deep brain stimulation. Study
participants’ demographics and clinical information can be found in Supplementary Tables S1 and S2.
Ethical approval and consent to participate
The study was approved by the respective local ethics committees of the University of Dundee in the United
Kingdom and the University of Tuebingen in Germany. All participants gave written informed consent.
Neutrophil isolation, characterisation, treatments and lysis
Neutrophils were isolated directly from human whole blood by immune-magnetic negative isolation using the
EasySep Direct Human Neutrophil Isolation Kit (STEMCELL Technologies, Cat# 19666). Twenty millilitres of
blood were transferred into a 50 ml falcon tube containing 200 ml of 100 mM EDTA in phosphate-buffered
saline (PBS) to obtain a ﬁnal concentration of EDTA at 1 mM, and tubes were gently mixed by inversion. One
millilitre of ‘Isolation Cocktail’ from the neutrophil isolation kit was added to the whole blood (i.e. 50 ml/ml of
blood). The ‘RapidSpheres’ magnetic beads from the isolation kit were resuspended by vortexing for 30 s and
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1 ml of beads were added to the whole blood (i.e. 50 ml/ml of blood). The blood sample containing the mag-
netic beads was gently mixed by inversion and incubated at room temperature for 5 min. The blood sample
was then diluted to a ﬁnal volume of 50 ml with 1 mM EDTA in PBS and then gently mixed by inversion of
the tube. The falcon tube was next placed into the Easy 50 EasySep Magnet (STEMCELL Technologies, Cat#
18002) without lid (to avoid subsequent agitation of tube) and incubated for 10 min at room temperature to
remove non-neutrophil blood cells. The supernatant (∼40 ml) containing the enriched neutrophils was care-
fully pipetted into a new 50 ml falcon tube, avoiding disrupting the magnetic beads attached to the sides of the
falcon tube that is in contact with the magnet as well as the red blood cells that were accumulated at the
bottom of the tube (typically present in the remaining ∼10 ml). To further purify neutrophils, another 1 ml of
resuspended RapidSpheres magnetic beads was added to the enriched neutrophils (i.e. 50 ml/ml of blood), the
tube was gently mixed by tube inversion and incubated at room temperature for 5 min. The tube was then
placed into the EasySep Magnet without lid and after 5 min incubation at room temperature, the supernatant
containing highly puriﬁed neutrophils was carefully pipetted into a new 50 ml falcon tube, taking care to
collect only the clear fraction. To ensure complete removal of magnetic beads from the cell mixture, the result-
ing neutrophils were placed for a ﬁnal time in the magnet (without lid). After a 10 min incubation at room
temperature, the pure neutrophil cell suspension was carefully pipetted into a new tube, ensuring that only the
clear fraction was collected (which will be ∼30 ml at this stage). The resulting isolated neutrophils were diluted
in PBS containing 1 mM EDTA to a ﬁnal volume of 41 ml and then divided equally into two tubes (each con-
taining 20 ml), one for LRRK2 inhibitor MLi-2 treatment and one for vehicle control DMSO treatment, and
1 ml of neutrophil suspension was kept for cell counting, viability and purity analysis using ﬂow cytometer.
The two 20 ml neutrophil preparations were then centrifuged at 335 g for 5 min (acceleration and deceleration
is both 5 using a Beckman Coulter Allegra X-15R Centrifuge), and the supernatant was carefully poured away.
The neutrophil cell pellets were resuspended with 10 ml room temperature RPMI 1640 media by gentle pipet-
ting. At this stage, puriﬁed neutrophils were subjected to with or without MLi-2 treatment at concentrations
and periods of time as indicated in each ﬁgure legend (typically 30 min). MLi-2 was dissolved in DMSO at a
concentration of 1000-fold higher than the ﬁnal concentrations added to neutrophils. An equivalent volume of
DMSO was added to negative control samples. Following treatment, neutrophils were pelleted through centrifu-
gation at 335 g for 5 min. Neutrophil pellets were then resuspended in 1 ml of RPMI 1640 media with or
without original concentrations of MLi-2, transferred into an Eppendorf tube and centrifuged at 300 g for
3 min. The supernatant was carefully removed by pipetting, and neutrophil pellet was lysed with 100 ml of
ice-cold lysis buffer containing 50 mM Tris–HCl, pH 7.5, 1% (v/v) Triton X-100, 1 mM EGTA, 1 mM sodium
orthovanadate, 50 mM NaF, 0.1% (v/v) 2-mercaptoethanol, 10 mM 2-glycerophosphate, 5 mM sodium pyro-
phosphate, 0.1 mg/ml mycrocystin-LR (Enzo Life Sciences), 270 mM sucrose, 0.5 mM DIFP (Sigma, Cat#
D0879) in addition to Complete EDTA-free protease inhibitor cocktail (Sigma–Aldrich, Cat# 11836170001).
DIFP is highly toxic and must be prepared in a fume hood to a stock solution of 0.5 M in isopropanol. This
stock solution of DIFP is stored at −80°C and stable for over 1 year. Dr Len Stephens from the Babraham
Institute in Cambridge, U.K., recommended that DIFP was used instead of PMSF for neutrophil lysis buffer, in
order to suppress the intrinsic serine protease activity that is known to be high in neutrophils [33] (D. Alessi
personal communication). DIFP is added freshly to lysis buffer from the isopropanol solution in a fume hood
just prior to lysing cells. Neutrophil cell lysates were clariﬁed by centrifugation at 20 800 g for 15 min at 4°C.
Supernatants were used for Bradford assay (Thermo Scientiﬁc) and snap-frozen and stored at −80°C.
The viability and purity of neutrophils after isolation using the ∼1 ml remaining sample was checked through
ﬂow cytometry analysis. Isolated cells were incubated with 2.5 mg of human FC block (BD Biosciences, Cat#
564220) in 100 ml FACS buffer for 10 min at room temperature. FACS buffer comprised of Dulbecco’s PBS
(Thermo Fisher Scientiﬁc, Cat# 14190094) + 1% foetal bovine serum (FBS) (Thermo Fisher Scientiﬁc, Cat#
10270106). After blocking, cells were stained with the granulocyte-speciﬁc cell surface marker CD66b using anti-
human CD66b-FITC antibody (BD Biosciences, Cat# 555724, clone G10F5). Antibody was used at a ﬁnal dilution
of 1 : 5 according to the manufacturer’s instructions. Cells were also stained with 40,6-diamidino-2-phenylindole
(DAPI, Thermo Fisher Scientiﬁc, Cat# D1306) at 2.5 mg/ml before analysis on a FACSVerse ﬂow cytometer with
FACSuite software (BD Biosciences). Data were analysed using FlowJo software (FlowJo, LLC).
PBMC isolation, characterisation, treatments and lysis
PBMCs were puriﬁed from 15 ml human whole blood via density centrifugation using Ficoll-Paque PREMIUM
(GE Healthcare, Cat# 17-5442-02). Blood was collected using BD Vacutainer sodium heparin (17 IU/ml) tubes,
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green closure 16 × 100 mm (BD, cat# 368480). Fifteen millilitres of Ficoll-Paque were added into the
SepMate™ tube (STEMCELL, Cat# 85450, 50 ml capacity) using a syringe through the central hole of the
SepMate™ insert to completely ﬁll the bottom cavity. Whole blood (15 ml) was diluted with an equal amount
(15 ml) of PBS containing 2% (by vol) FBS before being added into the top part of the SepMate™ tube. After
centrifugation at 1200 g for 10 min at room temperature (with the brake ON), the top plasma transparent layer
was discarded and the remainder cloudy layer of sample above the insert disk that contains the PBMCs was
collected and transferred to a new 15 ml falcon tube. The sample was then diluted with PBS containing 2% (by
vol) FBS to a ﬁnal volume of 15 ml, and the cells were gently mixed by tube inversion. PBMCs were pelleted
by centrifugation at 1000 g for 2 min. The supernatant was discarded by pouring and the PBMC pellet was
resuspended in 15 ml of PBS containing 2% FBS (by vol) for a second round of washing. After centrifugation
at 1000 g for 2 min, the PBMC pellet was then resuspended in 10.5 ml PBS containing 2% FBS. The PBMC
suspension was aliquoted into two tubes of 5 ml each for with or without MLi-2 inhibitor treatment, and the
remaining ∼0.5 ml of PBMCs used for, viability, and purity analysis by ﬂow cytometry analysis. At this stage,
puriﬁed PBMCs were subjected to with or without 200 nM MLi-2 treatment for 30 min. MLi-2 was dissolved
in DMSO at a concentration of 200 mM (1000-fold higher than the ﬁnal concentration) and 5 ml was added to
the +MLi-2 sample and an equivalent volume of DMSO (5 ml) also added to the −MLi-2 sample. Following
30 min incubation at room temperature, the supernatant was discarded by pouring. PBMC pellets are then
resuspended in 0.5 ml of PBS containing 2% FBS with or without 200 nM MLi-2, transferred into an
Eppendorf tube and centrifuged at 300 g for 3 min. The supernatant was carefully removed by pipetting and
PBMC pellet was lysed with 200 ml of ice-cold lysis buffer containing 50 mM Tris–HCl, pH 7.5, 1% (v/v)
Triton X-100, 1 mM EGTA, 1 mM sodium orthovanadate, 50 mM NaF, 0.1% (v/v) 2-mercaptoethanol, 10 mM
2-glycerophosphate, 5 mM sodium pyrophosphate, 0.1 mg/ml mycrocystin-LR (Enzo Life Sciences), 270 mM
sucrose, 0.5 mM DIFP (Sigma, Cat# D0879) in addition to Complete EDTA-free protease inhibitor cocktail
(Sigma–Aldrich Cat # 11836170001). DIFP is highly toxic and must be prepared in a fume hood to a stock
solution of 0.5 M in isopropanol. This stock solution of DIFP is stored at −80°C and stable for over 1 year.
DIFP is added freshly to lysis buffer from the isopropanol solution in a fume hood just prior to lysing cells.
PBMC cell lysates were clariﬁed by centrifugation at 20 800 g for 15 min at 4°C. Supernatants were used for the
Bradford assay (Thermo Scientiﬁc) and snap-frozen and stored at −80°C.
For viability and cell population determination via ﬂow cytometry analysis, PBMCs were FC-blocked as
described above for neutrophils, before staining with the following cell surface markers: CD19 APC (B-cell
marker, BD Biosciences, Cat# 561 742, clone HIB19) at 1 : 5 dilution, CD14 V500 (monocyte marker, BD
Biosciences, Cat# 561392, clone M5E2) at 1 : 20 dilution, CD3 PE (T-cell marker, BD Biosciences, Cat# 561808,
clone UCHT1) at 1 : 5 dilution and CD66b FITC (granulocyte marker, BD Biosciences, Cat# 555724, clone
G10F5) at 1 : 5 dilution. Cells were also stained with DAPI (Thermo Fisher Scientiﬁc, Cat# D1306) at 2.5 mg/
ml before analysis on a FACS LSR Fortessa ﬂow cytometer with DIVA software (BD Biosciences). Data were
analysed using FlowJo software (FlowJo, LLC).
Quantitative immunoblot analysis
Cell lysates were mixed with 4× SDS–PAGE loading buffer [250 mM Tris–HCl, pH 6.8, 8% (w/v) SDS, 40% (v/
v) glycerol, 0.02% (w/v) Bromophenol Blue and 4% (v/v) 2-mercaptoethanol] to a ﬁnal total protein concentra-
tion of 1 mg/ml and heated at 70°C for 10 min. Ten microgram of samples were loaded onto NuPAGE 4–12%
Bis–Tris Midi Gel (Thermo Fisher Scientiﬁc, Cat# WG1403BOX) and electrophoresed at 130 V for 2 h with
the NuPAGE MOPS SDS running buffer (Thermo Fisher Scientiﬁc, Cat# NP0001-02). At the end of electro-
phoresis, proteins were electrophoretically transferred onto the nitrocellulose membrane (GE Healthcare,
Amersham Protran Supported 0.45 mm NC) at 100 V for 90 min on ice in the transfer buffer (48 mM Tris–
HCl and 39 mM glycine). Transferred membrane was blocked with 5% (w/v) skim milk powder dissolved in
TBS-T [20 mM Tris–HCl, pH 7.5, 150 mM NaCl and 0.1% (v/v) Tween 20] at room temperature for 1 h. The
membrane was then cropped into three pieces, namely the ‘top piece’ (from the top of the membrane to
75 kDa), the ‘middle piece’ (between 75 and 30 kDa) and the ‘bottom piece’ (from 30 kDa to the bottom of the
membrane). The top piece was incubated with rabbit anti-LRRK2 pS935 UDD2 antibody multiplexed with
mouse anti-LRRK2 C-terminus total antibody diluted in 5% (w/v) skim milk powder in TBS-T to a ﬁnal con-
centration of 1 mg/ml for each of the antibody. The middle piece was incubated with mouse anti-GAPDH anti-
body diluted in 5% (w/v) skim milk powder in TBS-T to a ﬁnal concentration of 50 ng/ml. The bottom pieces
were incubated with rabbit MJFF-pRAB10clone-1 monoclonal antibody multiplexed with mouse MJFF-total
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Rab10clone-1 monoclonal antibody diluted in 2% (w/v) bovine serum albumin in TBS-T to a ﬁnal concentration
of 0.5 mg/ml for each of the antibody. All blots were incubated in primary antibody overnight at 4°C. Prior to
secondary antibody incubation, membranes were washed three times with TBS-T for 10 min each. The top and
bottom pieces were incubated with goat anti-mouse IRDye 680LT (#926-68020) secondary antibody multi-
plexed with goat anti-rabbit IRDye 800CW ((#926-32211) secondary antibody diluted in TBS-T (1 : 10 000 dilu-
tion) for 1 h at room temperature. The middle piece was incubated with goat anti-mouse IRDye 800CW
(#926-32210) secondary antibody diluted in TBS-T (1 : 10 000 dilution) at room temperature for 1 h.
Membranes were washed with TBS-T for three times with a 10 min incubation for each wash. Protein bands
were acquired via near infrared ﬂuorescent detection using the Odyssey CLx imaging system and quantiﬁed
using the Image Studio software.
Phos-tag polyacrylamide gel electrophoresis
Phos-tag acrylamide was stored at 5 mM aqueous solution (3.43 mg of compound in 1 ml of solution) at −80°
C in black tubes that block out light as Phos-tag acrylamide is light-sensitive. HPLC analysis of stock Phos-tag
acrylamide was undertaken every 4–5 weeks to ensure stock had not started to polymerise. Phos-tag analysis
including sample preparation was undertaken as described recently [15]. Brieﬂy, Phos-tag SDS–PAGE samples
were supplemented with MnCl2 to a ﬁnal concentration of 10 mM before loading gels. Gels for Phos-tag SDS–
PAGE consisted of a stacking gel [4% (w/v) acrylamide, 125 mM Tris–HCl, pH 6.8, 0.1% (w/v) SDS, 0.2% (v/v)
N,N,N0,N0-tetramethylethylenediamine (TEMED) and 0.08% (w/v) ammonium persulfate (APS)] and a separat-
ing gel [12% (w/v) acrylamide, 375 mM Tris/HCl, pH 8.8, 0.1% (w/v) SDS, 75 mM Phos-tag acrylamide,
150 mM MnCl2, 0.1% (v/v) TEMED and 0.05% (w/v) APS]. After centrifugation at 20 800 g for 1 min, 10 mg
of samples were loaded and electrophoresed at 70 V for the stacking part and at 120 V for the separating part
with the running buffer [25 mM Tris–HCl, 192 mM glycine and 0.1% (w/v) SDS]. For immunoblot analysis,
gels were washed for 10 min in the transfer buffer [48 mM Tris–HCl, 39 mM glycine and 20% (v/v) methanol]
containing 10 mM EDTA and 0.05% (w/v) SDS three times, followed by one wash in the transfer buffer con-
taining 0.05% SDS for 10 min. Proteins were electrophoretically transferred onto nitrocellulose membranes
(Amersham Protran 0.45 mm NC; GE Healthcare) at 100 V for 180 min on ice in the transfer buffer (48 mM
Tris–HCl and 39 mM glycine). Transferred membranes were blocked with 5% (w/v) skim milk powder dis-
solved in TBS-T [20 mM Tris–HCl, pH 7.5, 150 mM NaCl and 0.1% (v/v) Tween 20] at room temperature for
1 h. Membranes were then incubated with primary antibodies diluted in 5% (w/v) skim milk powder or 2% (w/
v) bovine serum albumin in TBS-T overnight at 4°C. After washing membranes in TBS-T, membranes were
incubated with secondary antibody (horseradish peroxidase-labelled secondary antibodies diluted in 5% skim
milk powder in TBS-T) for Phos-tag immunoblot at room temperature for 1 h. After washing membranes in
TBS-T, protein bands were detected by exposing ﬁlms [Amersham Hyperﬁlm ECL (GE Healthcare)] to the
membranes using an ECL solution [SuperSignal West Dura Extended Duration (Thermo Fisher Scientiﬁc)].
Results
Neutrophils are a homogenous peripheral blood cell population that express
high levels of LRRK2 and Rab10
To gain insights into the expression of the LRRK2 and Rab10 proteins in human peripheral blood cells, we
interrogated the IMMPROT proteomic database (http://www.immprot.org/) [34]. This suggests that LRRK2 is
highly expressed in neutrophils (∼2 × 105 copies per cells) as well as monocytes (∼1 × 105 copies per cells), but
is virtually undetectable in B and T lymphocytes as well as natural killer and dendritic cells that constitute
most of the PBMCs (Figure 1). Rab10 is also highly expressed in neutrophils and monocytes (2–4 × 106 copies
per cells) and is up to 10-fold less abundant in all other PBMCs (2–4 × 105 copies per cell) (Figure 1). Blood
cell-type frequencies vary from donor to donor; however, neutrophils are the most abundant white blood cell
(37–80% of the white blood cells), while PBMCs are a heterogeneous cell population and are generally less
abundant (10–62% of the white blood cells) [35].
Analysis of LRRK2-mediated Rab10 phosphorylation in human neutrophils by
quantitative immunoblot analysis
To our knowledge, the LRRK2 pathway activity has not been assessed in human neutrophils before. We there-
fore isolated neutrophils from peripheral blood from 12 healthy volunteers exploiting an immunomagnetic
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negative isolation approach, in which all non-neutrophils are targeted for removal with antibody complexes rec-
ognizing unwanted cells, including red blood cells and platelets, leaving only neutrophils in the supernatant.
Flow cytometry analysis with the CD66b− Fluorescein isothiocyanate neutrophil marker revealed that the
purity of neutrophils isolated from each volunteer was 97–99% and viability of cells was ∼99% assessed with
DAPI staining (Figure 2A and Supplementary Figure S2). From 20 ml of blood, we obtained 0.2–1.4 mg of
total protein from each donor (Figure 2A), sufﬁcient for a signiﬁcant number of immunoblot analysis that
requires only 10 mg per gel lane due to the high-quality antibodies that were deployed for the assay.
To ensure that observed LRRK2 Ser935 and Rab10 phosphorylation was mediated by LRRK2, we incubated
each batch of neutrophils with or without 100 nM MLi-2, a very selective and potent LRRK2 inhibitor [26,27].
Neutrophils were lysed in a buffer containing the protease inhibitor DIFP in order to suppress intrinsic serine
protease activity that is known to be high in these cells [33]. Immunoblot analysis with an LRRK2 total
Figure 1. The abundance of LRRK2 and RAB10 proteins in immune cells isolated from human blood using data
available from the immprot database (http://www.immprot.org) [34].
The study utilised pure populations of immune cells isolated from human blood using ﬂuorescence-activated cell sorting, and
whole cell proteomics data were generated. Data were analysed using the histone ruler to estimate protein copy numbers per
cell. The graphs show the number of protein copies per cell for LRRK2 and RAB10 in a range of peripheral blood immune cells
including subsets of T cells, B cells, monocytes, NK cells, dendritic cells and the granulocytes neutrophils, basophils and
eosinophils.
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Figure 2. Monitoring LRRK2-mediated Ser935 and Rab10 phosphorylation in human neutrophils.
Neutrophils were isolated from 12 healthy donors and treated with or without 100 nM MLi-2 for 30 min. (A) Viability (DAPI) and
purity (CD66b) of neutrophils isolated from whole blood of 12 healthy volunteers were assessed via ﬂow cytometer analysis.
(B and C) Neutrophils were then lysed and 10 mg of whole cell extract subjected to quantitative immunoblot analysis with the
indicated antibodies (all at 1 mg/ml antibody) and the membranes were developed using the Odyssey CLx scan Western Blot
imaging system. Similar results were obtained in two independent experiments. Quantitation of immunoblots was undertaken
by analysing LRRK2 (full length)/GAPDH ratio (Bi), total LRRK2 (170 kDa species)/GAPDH ratio (Bii), phospho-Ser935 LRRK2
(full length)/total LRRK2 (full length) ratio (Biii) and phospho-Ser935 LRRK2 (170 kDa species)/total LRRK2 (170 kDa species)
ratio (Biv), total Rab10/GAPDH ratio (Ci), phospho-Thr73 Rab10/GAPDH ratio (Cii) and phospho-Thr73 Rab10/total Rab10 ratio
(Ciii).
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antibody recognising the C-terminal domain revealed two species migrating at ∼286 kDa (corresponding to
full-length LRRK2) and ∼170 kDa (Figure 2B). The ∼170 kDa LRRK2 species was 2- to 3-fold more abundant
than the full-length LRRK2 and is likely to correspond to an N-terminally truncated form, as it is not recog-
nised by an antibody raised against the N-terminal domain of LRRK2 (Figure 2B). The levels of the full-length
LRRK2 were very similar in all samples (Figure 2Bi), but levels of the ∼170 kDa species varied more
(Figure 2Bii). Furthermore, we also noticed that treatment with MLi-2 induced a moderate reduction in the
amount of the ∼170 kDa species (Figure 2Bii) without affecting levels of the full-length form (Figure 2Bi).
Immunoblotting with the LRRK2 Ser935 phospho-speciﬁc antibody revealed that the full-length and ∼170 kDa
species of LRRK2 were phosphorylated at Ser935 and both became dephosphorylated following MLi-2 treat-
ment (Figure 2Biii,iv). Quantitative immunoblot analysis revealed that both the full-length and the ∼170 kDa
species of LRRK2 are similarly phosphorylated at Ser935 in all 12 neutrophil samples, with less than 1.5-fold
variance between the samples (Figure 2Biii,iv).
Immunoblotting using the MJFF-pRab10 monoclonal antibody revealed a robust signal in all neutrophil
samples, which was markedly suppressed by MLi-2 LRRK2 inhibitor treatment (Figure 2C). Rab10 protein
expression was also similar in all 12 neutrophil samples with less than 2-fold difference observed (Figure 2Ci).
We quantiﬁed Rab10 phosphorylation by either normalising against GAPDH (Figure 2Cii) or total Rab10
(Figure 2Ciii), and both revealed a similar relative pattern of phosphorylation between samples. The level of
Rab10 phosphorylation varied ∼2-fold among samples, greater than that observed with Ser935 phosphorylation
(Figure 2Biv,Ciii). For example, donor 6 (low Rab10 phosphorylation) and donor 8 (high Rab10 phosphoryl-
ation) have an ∼2-fold difference in Rab10 phosphorylation (Figure 2Ciii), while displaying similar levels of
Ser935 phosphorylation (Figure 2Biii,iv).
LRRK2-mediated Rab10 phosphorylation in neutrophils from control and
Parkinson’s patients with and without the LRRK2 G2019S mutation
We next explored the feasibility of analysing LRRK2 pathway activity in neutrophils isolated from a small
number of Parkinson’s patients with and without the G2019S LRRK2 mutation. The purpose of the present
study was to test the practicability of assessing LRRK2-mediated Rab10 phosphorylation in a patient cohort in
a clinical setting and not to address whether Rab10 phosphorylation is elevated in patients with Parkinson’s or
G2019S carriers. To answer this question, further studies with much larger numbers of patients and controls
will be required.
Neutrophils were isolated from 13 healthy controls, 7 patients with sporadic Parkinson’s and 6 individuals
with a heterozygous G2019S LRRK2 mutation — 5 with Parkinson’s and 1 non-manifesting carrier (Figures 3–
5). Demographic and clinical data for each subject are presented in Supplementary Tables S1 and S2. As
before, each participant’s neutrophils were treated with or without 100 nM MLi-2 LRRK2 inhibitor for 30 min
at room temperature before cell lysis. Samples were subjected to quantitative immunoblot analysis with total
LRRK2, pSer935 LRRK2, total Rab10, MJFF-pRAB10 (pThr73) and a loading control GAPDH antibody. Levels
of full-length LRRK2 varied by ∼8 fold among all the donors (Figure 4A), while levels of ∼170 kDa LRRK2
species varied ∼3-fold (Figure 4B). Ser935/total full-length LRRK2 varied ∼1.5-fold between donors
(Figure 4C), while there was ∼3-fold variance between total Rab10 levels (Figure 4D) with no signiﬁcant differ-
ences between healthy controls, sporadic Parkinson’s disease and heterozygous G2019S LRRK2 mutation car-
riers for any of these analysis (Figure 4).
We quantiﬁed Rab10 phosphorylation in four different ways, by normalising pRab10 signal obtained with no
MLi-2 treatment with either GAPDH (Figure 5A) or total Rab10 (Figure 5B), or by subtracting the phosphory-
lated Rab10 signal from samples treated plus MLi-2 from untreated samples and normalising with GAPDH
(Figure 5C) or total Rab10 (Figure 5D). As observed with the healthy donor samples (Figure 2), there was
greater variation in Rab10 phosphorylation between the individual participants in our study and a clear reduc-
tion in Rab10 phosphorylation upon LRRK2 inhibition (Figure 5). The data is broadly comparable for all four
ways of quantifying Rab10 phosphorylation. For example, donor 22 (G2019S) and donor 25 (sporadic) consist-
ently show the lowest level of Rab10 phosphorylation, whichever way the data are quantiﬁed (Figure 5).
Similarly, donor 1 and donor 20 (both G2019S) as well as donor 8 and donor 24 (both sporadic) display
among the highest levels of Rab10 phosphorylation in all ways that the data are analysed (Figure 5). As
expected, from the small number of clinical samples, we did not obtain statistically signiﬁcant differences in
Rab10 phosphorylation between any of the groups (Figure 5). This is considered further in the discussion.
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Curiously, donor 22 (G2019S) who displayed unusually low levels of phosphorylated Rab10 (Figure 5C,D) had
relatively high levels of LRRK2 Ser935 phosphorylation (Figure 4C).
Side-by-side comparison of LRRK2-mediated phosphorylation of Rab10 in
neutrophils and PBMCs
To compare LRRK2-mediated phosphorylation of Rab10 in neutrophils and PBMCs, we isolated neutrophils
and PBMCs from the same healthy donors (Figure 6). Flow cytometry was used to assess the proportion of B
cells (CD19-positive), monocytes (CD14-positive), T cells (CD3-positive) and contaminating neutrophils
(CD66b-positive) in each of the six PBMC preparations (Supplementary Figure S3). This conﬁrmed expected
heterogeneity of PBMCs, with levels of monocytes ranging from 6.6 to 15%, B cells from 3.8 to 16%, T cells
from 55 to 65% and contaminating neutrophils from 1 to 6% (Supplementary Figure S3).
Immunoblot analysis of PBMCs revealed that full-length LRRK2 was the major species, with only low levels
of the ∼170 kDa form observed. Full-length LRRK2 levels were 20- to 30-fold higher in PBMCs compared with
neutrophils (Figure 6Bi). Levels of Ser935 phosphorylation normalised to full-length LRRK2 were similar in
PBMCs and neutrophils from different donors, with less than 1.5-fold variance between the six donors
(Figure 6Biii). Although levels of Rab10 protein were similar in neutrophil and PBMC preparations
(Figure 6Bii), 2.5- to 6-fold higher levels of Rab10 Thr73 phosphorylation were observed in neutrophil samples
compared with PBMCs (Figure 6Biv). Neutrophils from donor 1, 5 and 6 displayed ∼2-fold higher phosphoryl-
ation of Rab10 than other donors, but this increase was not observed in PBMC samples from these donors
(Figure 6iv).
Figure 3. Analysing LRRK2-mediated Rab10 phosphorylation in neutrophils from control and Parkinson’s patients.
Neutrophils were isolated from 13 healthy controls, 7 sporadic Parkinson’s disease patients and 6 individuals with a
heterozygous G2019S LRRK2 mutation — 5 with Parkinson’s disease and 1 carrier (Donor 20, highlighted in blue). Cells were
treated with or without 100 nM MLi-2 for 30 min. Cells were then lysed and 10 mg of whole cell extract subjected to
quantitative immunoblot analysis with the indicated antibodies (all at 1 mg/ml antibody), and the membranes developed using
the Odyssey CLx scan Western Blot imaging system. Similar results were obtained in three independent immunoblot
experiments of the same extracts.
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Figure 4. Quantitation of LRRK2, LRRK2 Ser935 phosphorylation and Rab10 in neutrophils from control and Parkinson’s
patients.
The immunoblots from Figure 3 were quantiﬁed for full-length LRRK2/GAPDH ratio (A), ∼170 kDa species of LRRK2/GAPDH
ratio (B), phospho-Ser935 LRRK2 (full length)/total LRRK2 (full length) ratio (C) and total Rab10/GAPDH ratio (D).
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Figure 5. Quantitation of LRRK2-mediated Rab10 phosphorylation in neutrophils from control and Parkinson’s patients.
The immunoblots from Figure 3 were quantiﬁed for phospho-Thr73 Rab10/GAPDH ratio (A), phospho-Thr73 Rab10/total Rab10
ratio (B), LRRK2-dependent phospho-Thr73 Rab10/GAPDH ratio (C) and LRRK2-dependent phospho-Thr73 Rab10/total Rab10
ratio (D). Data were analysed by one-way ANOVA with Bonferroni’s multiple comparisons test. Data presented as means ± SD;
*P < 0.05, **P < 0.005.
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Dose and time dependence of LRRK2 inhibitors on LRRK2 Ser935 and Rab10
phosphorylation in neutrophils
To assess LRRK2 inhibitor dose response, we treated human neutrophils with increasing concentrations of two
structurally diverse inhibitors namely MLi-2 [26] and PF-06447475 [36] for 30 min (Figure 7A). With MLi-2,
we saw no effect on Rab10 phosphorylation in doses up to 10 nM, a 50% reduction in phosphorylation with a
dose of 30 nM and a suppression of Rab10 phosphorylation to near basal levels with doses of 100 nM and
Figure 6. Comparison of LRRK2-mediated phosphorylation of Rab10 in neutrophils and PBMCs.
(A) Both neutrophils and PBMCs were prepared from the same six healthy donors and treated with or without 100 nM MLi-2 for
30 min. Cells were then lysed and 10 mg of whole cell extract subjected to quantitative immunoblot analysis with the indicated
antibodies (all at 1 mg/ml antibody) and the membranes were developed using the Odyssey CLx scan Western Blot imaging
system. (B) Quantitation of immunoblots was undertaken analysing total LRRK2 (full length)/GAPDH (Bi), total Rab10/GAPDH
ratio (Bii), phospho-Ser935 LRRK2 (full length)/total LRRK2 (full length) (Biii) and total phospho-Thr73 Rab10/total Rab10 (Biv).
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above (Figure 7Bi). The dose-dependence curve of the PF-06447475 inhibitor was similar with ∼50% inhibition
of Rab10 phosphorylation observed at 30 nM (Figure 7Bi). With regards to Ser935 phosphorylation, both
MLi-2 and PF-06447475 inhibited phosphorylation slightly more potently; i.e. moderate inhibition observed at
10 nM and 60–70% inhibition at 30 nM (Figure 7Bii).
Figure 7. Dose–response curve and time course analysis of LRRK2-mediated Rab 10 phosphorylation in neutrophils.
(A) Neutrophils were isolated from two healthy donors and treated with the indicated concentrations of MLi-2 or PF-06447475
for 30 min. Cells were then lysed and 10 mg of whole cell extract subjected to quantitative immunoblot analysis with the
indicated antibodies (all at 1 mg/ml antibody) and the membranes were developed using the Odyssey CLx scan Western Blot
imaging system. (B) Quantitation of immunoblots was undertaken by analysing phospho-Thr73 Rab10/total Rab10 ratio (Bi) and
phospho-Ser935 (full length)/total LRRK2 (full length) ratio (Bii). (C and D) Quantiﬁcation of immunoblots as above, phospho-
Thr73 Rab10/total Rab10 ratio (Di) and phospho-Ser935 (full length)/total LRRK2 (full length) ratio (Dii), except that neutrophils
were isolated from two healthy donors and treated with MLi-2 at concentrations of 100 nM for the indicated times. Similar
results were obtained in two independent experiments.
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We also explored the kinetics of the MLi-2 inhibitor mediated Rab10 Thr73 and LRRK2 Ser935 dephosphor-
ylation in human neutrophils, which revealed that Rab10 was fully dephosphorylated within 10 min following
treatment with 100 nM MLi-2 (Figure 7D). Dephosphorylation of LRRK2 Ser935 was slower, with only partial
dephosphorylation observed at 10 min and complete dephosphorylation at 30 min of MLi-2 treatment
(Figure 7E).
The importance of including DIFP in the neutrophil lysis buffer
As the DIFP protease inhibitor is a potent organophosphorus neurotoxin, we investigated whether it was essen-
tial to add this to the neutrophil lysis buffer. We therefore lysed human neutrophils with or without DIFP and,
in the ﬁrst instance, explored whether DIFP could be replaced with 1% (w/v) SDS, which has been used to lyse
neutrophils in other studies [37]. This strikingly revealed that when DIFP is substituted with 1% (w/v) SDS,
LRRK2, Rab10 and even the GAPDH loading control were undetectable, demonstrating the importance of
including a highly potent protease inhibitor (Figure 8A). We investigated whether it was possible to store the
lysis buffer containing DIFP at −20 or −80°C rather than having to add it to cell lysates immediately prior to
use. This revealed that frozen lysis buffer containing DIFP was as effective in preserving LRRK2, Rab10 and
GAPDH as the freshly prepared buffer (Figure 8B). Subsequently, we attempted to replace 0.5 mM DIFP with
2.5 mM PMSF, a less potent serine protease inhibitor that is not as toxic as DIFP. We found that Rab10
phosporylation was equally well preserved in PMSF-containing lysis buffer compared to DIFP-containing lysis
buffer (Figure 8C). However, the LRRK2 protein, especially the full-length form, was less well preserved with
PMSF compared with DIFP (Figure 8C).
Robust LRRK2-mediated Rab10 phosphorylation up to 24 h after venesection
We next explored whether a delay in purifying neutrophils from human blood would affect on
LRRK2-dependent Rab10 phosphorylation. Blood was drawn from three healthy donors and left unprocessed
at room temperature for up to 24 h before neutrophils were isolated and with or without MLi-2 inhibitor treat-
ment. Immunoblot analysis of these samples reveals that storing blood for up to 24 h does not compromise
LRRK2-dependent phosphorylation of Rab10 (Figure 9).
Monitoring LRRK2-mediated Rab10 phosphorylation in human neutrophils by
Phos-tag analysis
Finally, we investigated whether Rab10 phosphorylation in neutrophils could be monitored by employing the
Phos-tag assay, in which the retardation of LRRK2-phosphorylated Rab10 is visualised following Phos-tag poly-
acrylamide gel electrophoresis [15]. Neutrophils were prepared from 12 healthy volunteers, with or without
100 nM MLi-2 inhibitor treatment and subjected to Phos-tag analysis. As shown in Figure 10, LRRK2-mediated
phosphorylation of Rab10 was extremely hard to detect and high exposure of immunoblots was required to
observe the LRRK2 phosphorylated species of Rab10 that was sensitive to MLi-2 (Figure 10). Stoichiometry of
Rab10 phosphorylation was also exceedingly low (Figure 10).
Discussion
There is compelling evidence for the role of LRRK2 and in particular its kinase function in Parkinson’s disease.
This has sparked considerable interest in exploiting LRRK2 as a drug and biomarker target. Here, we describe a
facile and robust assay for monitoring LRRK2 kinase pathway activity by measuring its effect on phosphoryl-
ation of its physiological substrate Rab10 in (a) the homogenous pool of human peripheral blood neutrophils
and (b) with the use of a highly selective phospho-speciﬁc Rab10 antibody (MJFF-pRab10 monoclonal
antibody).
The rational for using human peripheral blood neutrophils is that they represent a homogenous subset of
cells that make up the dominant leukocyte population in humans [38–41]. More importantly, neutrophils
express relatively high levels of both LRRK2 and Rab10 [34] (Figure 1). In contrast, the remaining pool of leu-
kocytes, PBMCs, is heterogeneous, and LRRK2 and Rab10 expression is variable. Signiﬁcant expression of
LRRK2 in PBMCs is only found in monocytes [34] (Figure 1) that make up 5–20% of PBMCs. A priori, neu-
trophils appear to be the most suitable peripheral blood cell type for studying LRRK2 pathway activity. We
therefore developed a protocol for peripheral blood neutrophil puriﬁcation based on negative selection that,
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Figure 8. Assessing the importance of DIFP for the prevention of proteolytic degradation in neutrophils.
(A) Neutrophils were isolated from two healthy donors and treated with 100 nM MLi-2 for 30 min. Cells were lysed in the
presence or absence of SDS (1% by volume) and 0.5 mM DIFP as indicated. Whole cell extract (10 mg) subjected to
quantitative immunoblot analysis with the indicated antibodies (all at 1 mg/ml antibody) and the membranes were developed
using the Odyssey CLx scan Western Blot imaging system. Similar results were obtained in two independent experiments.
(B) As in (A) except that cells were lysed with freshly prepared lysis buffer containing 0.5 mM DIFP or the same buffer that had
been prepared 1 week ahead of time and stored at −20 or −80°C as indicated. Similar results were obtained in two
independent experiments. (C) As in (A), except that cells were lysed in the presence of either 0.5 mM (DIFP) or 2.5 mM
isopropanol PMSF. DIFP was prepared at 0.5 M in isopropanol and added to the lysis buffer immediately prior to use. PMSF
was dissolved at 0.1 M in isopropanol and added to the lysis buffer immediately prior to use.
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within 40 min of venesection, allows isolation of up to 99% pure and viable neutrophils while also yielding rela-
tively high amounts of protein (Figure 2A).
When looking at the total LRRK2 levels in neutrophil lysates, we noticed two bands: one at the expected size
for full-length LRRK2 at ∼286 kDa and a shorter one at ∼170 kDa. We suspect that the truncated ∼170 kDa
band corresponds to a proteolytic species lacking the N-terminal domain resulting from the high protease
activity present in neutrophils, but cannot exclude an alternative splice variant. To our knowledge, no other
LRRK2 isoform of that size has been reported [11,42]. The levels of both species of LRRK2 are fairly constant
among individual healthy donors (Figure 2Bi,ii), but full-length LRRK2 varied more in the patient samples we
analysed (Figure 4A,B). We also observed a moderate reduction in the ∼170 kDa form of LRRK2 after 30 min
MLi-2 treatment (Figure 2Bii), but not of the full-length LRRK2 (Figure 2Bi). This suggests that MLi-2 inhibi-
tor binding promotes degradation of the ∼170 kDa form of LRRK2. It has recently been reported that various
LRRK2 inhibitors induce destabilisation and degradation of LRRK2, generally over a longer period than 30 min
[43,44]. In contrast, a high dose of 1000 nM PF-06447475 did not affect LRRK2 levels, suggesting that this
Figure 9. Detection of LRRK2-mediated Rab phosphorylation in neutrophils isolated up to 24 h after venesection.
Blood was drawn from three healthy donors and left unprocessed at room temperature. At the indicated times, neutrophils
were isolated from the blood and treated with or without MLi-2 at 100 nM for 30 min. (A) Neutrophils were then lysed and
10 mg of whole cell extract subjected to quantitative immunoblot analysis with the indicated antibodies (all at 1 mg/ml antibody)
and the membranes were developed using the Odyssey CLx scan Western Blot imaging system. Similar results were obtained
in two independent experiments. (B) Quantitation of immunoblots was undertaken by analysing phospho-Thr73 Rab10/total
Rab10 ratio (top panel) and phospho-Ser935 (full length)/total LRRK2 (full length) ratio (bottom panel).
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effect will be dependent on the inhibitor used (Figure 7A). With regard to Rab10, expression levels are fairly
constant (Figures 2Ci and 4C).
For assessing LRRK2 kinase pathway activity, we have utilised the newly developed phospho-speciﬁc
MJFF-pRab10 monoclonal antibody that selectively recognises Rab10 phosphorylated by LRRK2 at Thr73 [18].
Unlike Ser935 LRRK2 (see Introduction), the Thr73 Rab10 site is directly phosphorylated by LRRK2 and
would be expected to represent a more reliable readout of LRRK2 kinase activity and inhibition thereof.
Consistent with the notion that Rab10 phosphorylation represents a more direct and dynamic reﬂection of
LRRK2 activity than Ser935 phosphorylation, we observed higher biological variation in the levels of Rab10
phosphorylation between the 12 healthy donors than with Ser935 phosphorylation (Figure 2Cii,iii). For the
purpose of quantifying Rab10 phosphorylation, normalisation can be undertaken using either total Rab10 or
GAPDH. It is also possible to calculate the change in phosphorylation of Rab10 observed with and without
MLi-2 and then normalise to either total Rab10 or GAPDH, to account for background Rab10 phosphorylation
(Figure 5C,D). Until more data is available, we would advocate normalising in all possible ways. In future
studies, we would also recommend using 200–300 nM MLi-2 (rather than 100 nM) to ensure that
LRRK2-mediated Rab10 phosphorylation is completely reduced, as we observed slightly enhanced suppression
of Rab10 phosphorylation at 300 nM MLi-2 compared with 100 nM (Figure 7A,Bi). Finally, the level of Rab10
phosphorylation does not depend on the total amount of Rab10 (Figures 2C and 4D).
The data obtained with the phospho-immunoblotting approach is vastly more robust and sensitive than the
Phos-tag method (compare Figure 2 with Figure 10). Comparison of these results highlights the quality and
sensitivity of the MJFF-pRab10 monoclonal antibody, which can readily assess low picogram levels of Rab10
phosphorylation in whole cell extracts [18]. We would not recommend the Phos-tag assay for the quantitative
assessment of Rab10 phosphorylation in neutrophils, in particular with a view towards clinical translation
(compare Figure 2 with Figure 10).
Paramount for the phospho-immunoblot approach is the availability of an antibody that is fully selective
against the Rab10 Thr73 phospho-epitope and does not cross-react with other phosphorylated Rab proteins.
Figure 10. Phosphorylation of endogenous Rab10 in human neutrophils analysed by Phos-tag polyacrylamide
electrophoresis.
Neutrophils were isolated from 12 healthy donors and treated with or without 100 nM MLi-2 for 30 min. Cells were then lysed
and 10 mg of whole cell extract subjected to electrophoresis in which the Phos-tag acrylamide was polymerised into the
polyacrylamide gel in order to retard the electrophoretic mobility of LRRK2-phosphorylated Rab10. The gels were subjected to
immunoblot analysis with an antibody that speciﬁcally recognises Rab10 (1 mg/ml antibody), and the band corresponding to
phosphorylated and non-phosphorylated Rab10 is marked with open and ﬁlled circles, respectively. A low (top panel), medium
(middle panel) and high exposure (bottom panel) of the immunoblot are shown. Similar results were obtained in two separate
experiments.
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Another phospho-Rab10 polyclonal antibody has recently been published [17], but its selectivity towards other
LRRK2 phosphorylated Rab proteins was not investigated. Based on our experience of generating numerous
phospho-polyclonal Rab10 antibodies in sheep and rabbit [18], it is unlikely that any polyclonal
phospho-Rab10 antibody would be selective. For future work, we recommend that only antibodies that have
been demonstrated to be selective for only a single LRRK2 phosphorylated Rab protein are employed for the
quantitative in vivo assessment of LRRK2 activity; similar to the characterisation of the MJFF-pRab10 anti-
bodies used in this study [18].
We went on to explore the practicability of using our assay in the clinical setting to test how sample collec-
tion, processing, as well as any other uncontrollable and unforeseeable aspects that are intrinsic to clinical prac-
tise might affect the outcome. We recruited 13 healthy controls, 7 patients with sporadic Parkinson’s, 5 patients
with G2019 LRRK2 associated Parkinson’s and 1 asymptomatic G2019S LRRK2 carrier (Supplementary Tables
S1 and S2). By including participants with LRRK2 G2019S associated Parkinson’s, we anticipated to gain more
insights into the effect size of LRRK2 kinase activity by means of Rab10 phosphorylation. In a mouse model, a
G2019S knock-in mutation in the homozygous state results in an ∼2-fold increase in Rab10 phosphorylation
[14,15,18]. One would therefore expect a lower, perhaps ∼1.5-fold increase in Rab10 phosphorylation in the
heterozygous state, which is equivalent to a G2019S heterozygous patient. This is a very modest change in
LRRK2 activity to measure against the background of normal biological variation in a patient. The detection of
a robust change in Rab10 phosphorylation would have required much larger numbers of participants to begin
with, if the aim had been to demonstrate a signiﬁcant difference between the groups. Therefore, the main result
is that our assay is robust and can be used in the clinical setting.
We speculate that G2019S LRRK2 mutation carriers would have the highest levels of Rab10 phosphorylation
followed by those with sporadic Parkinson’s, while healthy controls would have the lowest levels. This trend is
observed when LRRK2-mediated Rab10 phosphorylation is normalised to GAPDH (Figure 5A,C). In the
G2019S group, there was one patient, donor 22 (Supplementary Table S2), with much lower Rab10 phosphoryl-
ation which brings the group’s average down (Figure 5). In future work, it would be interesting to include
patients with other pathogenic LRRK2 mutations, for example the Basque R1441G LRRK2 mutation. This
mutation is of particular relevance in terms of proof-of-principle, as studies in R1441G/C knock-in mouse
models have shown to have an at least 2-fold greater effect on LRRK2-mediated Rab10 phosphorylation than
the G2019S mutation [14,15,18].
As many other groups have studied LRRK2 in PBMCs [17,45,46] and international Parkinson’s
bio-repositories collect PBMCs and as far as we are aware of not neutrophils, we undertook a side-by-side com-
parison of neutrophils and PBMCs. In PBMCs, robust levels of LRRK2 and total Rab10 were observed, with
the full-length LRRK2 being the predominant species (Figure 6). From published mass spectrometry data, one
would expect that neutrophils display higher LRRK2 activity than PBMCs [34] (Figure 1). Consistent with this,
we observe 2.5- to 6-fold higher phosphorylation of Rab10 in neutrophils compared with PBMCs (Figure 6).
Although immunoblotting does not reveal higher levels of LRRK2 in neutrophils, this is likely explained by
LRRK2 undergoing considerable proteolytic degradation in neutrophil extracts when compared with PBMCs.
In our opinion, due to the heterogeneity of LRRK2 expressing cells in PBMCs, PBMCs may be unsuitable for
the purpose of monitoring in vivo LRRK2 kinase pathway activity with Rab10 phosphorylation as a readout.
We would also recommend that Parkinson’s bio-repositories consider including neutrophils as an additional
bioresource.
The IC50 for MLi-2 on Rab10 Thr73 dephosphorylation in neutrophils (30 nM) is higher than what has pre-
viously been observed in mouse embryonic ﬁbroblasts (3–10 nM) [15] (Figure 7Bi). This slightly higher IC50
value could be explained by the high levels of LRRK2 activity in neutrophils (Figure 1). The IC50 for
PF-06447475 on Rab10 dephosphorylation has not been reported. Time course analysis reveals that almost
complete dephosphorylation of Rab10 Thr73 is achieved within 10 min, while LRRK2 Ser935 dephosphoryla-
tion is more protracted. This is similar to what was observed in mouse embryonic ﬁbroblasts [15], suggesting
that Rab proteins are dephosphorylated rapidly after inhibition of LRRK2. As at least 30 min are required for
maximal dephosphorylation of Ser935, it is important to maintain the LRRK2 inhibitor treatment period at
30 min in future studies (Figure 7D,E). Our work also demonstrates that standard lysis buffer not containing
serine protease inhibitors is not sufﬁcient to preserve LRRK2 and Rab10 proteins in neutrophil lysates
(Figure 8A). Throughout the present study we have used the highly potent serine protease inhibitor DIFP
(0.5 mM), as part of our neutrophil lysis buffer (Figure 8A). To minimise handling and exposure to DIFP,
which is highly toxic, we have successfully shown that pre-prepared lysis buffer containing DIFP can be
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aliquoted and stored at −20°C or −80°C for subsequent use (Figure 8B). We have also substituted DIFP with
PMSF (2.5 mM), which is a less potent serine protease inhibitor. At least for monitoring the Rab10 protein as
well as its phosphorylation, PMSF works well (Figure 8C). However, we ﬁnd that PMSF is less efﬁcient at pre-
serving LRRK2. As discussed above, LRRK2 is much more susceptible to proteolysis in particular in neutrophils
when compared with other cell types such as PBMCs. In future work, it would be interesting to evaluate other
serine protease inhibitors and/or other protein lysis strategies, to explore avenues for improved preservation of
the LRRK2 protein in neutrophils.
In summary, we have developed an assay to robustly measure LRRK2 kinase pathway activity by monitoring
Rab10 phosphorylation in human peripheral blood neutrophils. Neuroprotective and disease-modifying trials
in neurodegenerative conditions have largely failed in the past. There is reasonable hope that this may be differ-
ent in LRRK2 associated Parkinson’s. Orally bioavailable, brain penetrant LRRK2 inhibitors have been gener-
ated and individuals who have not yet developed or are early on in their disease course can be genetically
stratiﬁed based on their LRRK2 genotype. Measuring LRRK2-mediated phosphorylation of Rab10 in neutro-
phils or other tissues might represent a biomarker that allows for additional patient stratiﬁcation. We acknow-
ledge that this may be challenging due to the moderate changes of LRRK2 kinase activity associated with
pathogenic mutations. Also, our assay captures a peripheral rather than a central readout of LRRK2 kinase
function, but to date no non-invasive central measure of LRRK2 activity exists. In the present study, we have
highlighted key considerations why neutrophils are a useful biomaterial for analysing LRRK2 pathway activity
and the importance of using highly speciﬁc phospho-Rab protein antibodies. We also demonstrate the relative
ease and feasibility of performing our assay in the clinical setting. We envision that our LRRK2 kinase pathway
assay may ﬁnd wider use for pharmacodynamic and target engagement studies for future LRRK2 inhibitor clin-
ical trials. In future work, it would also be exciting to explore the biological role that the LRRK2 pathway
plays in neutrophils and whether it is involved in controlling migration to the sites of the infection and/or
phagocytosis and destruction of pathogens.
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